Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973866 · ClinicalTrials.gov registry record · NA
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
A NA study, sponsored by Sequana Medical N.V..
- Active
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT03973866: Active NA study, sponsored by Sequana Medical N.V..
NCT03973866 is a NA study that is active but no longer recruiting, run by Sequana Medical N.V.. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03973866, a NA study, is active but no longer recruiting, sponsored by Sequana Medical N.V..
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation phase after enrollment, followed by implantation of the alfapump and 24 months of post-implant follow up. An analysis will be conducted to support an application for device approval when a minimum of 40 treated pivotal cohort patients are through 6 months.
Primary Outcome
Defined as removal of ascites ≥1.5L through needle puncture of abdominal wall
Interventions
- DEVICE Alfapump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
What the registry record for NCT03973866 still lists
NCT03973866 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Alfapump is the first listed.
NCT03973866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03973866 about?
NCT03973866 is a clinical study titled "Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)". The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation ph...
What is the current status of trial NCT03973866?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2019-09-16. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03973866?
The interventions under investigation include: Alfapump (DEVICE).
Who is sponsoring clinical trial NCT03973866?
This trial is sponsored by Sequana Medical N.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03973866's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI